Genesis Private Wealth LLC Increases Holdings in Kenvue Inc. $KVUE

Genesis Private Wealth LLC lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 20.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,021 shares of the company’s stock after acquiring an additional 2,337 shares during the quarter. Genesis Private Wealth LLC’s holdings in Kenvue were worth $293,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. raised its position in shares of Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares during the last quarter. Arlington Partners LLC acquired a new position in shares of Kenvue during the 2nd quarter worth approximately $2,110,000. Farther Finance Advisors LLC raised its position in shares of Kenvue by 80.7% during the 2nd quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock worth $758,000 after purchasing an additional 16,164 shares during the last quarter. IFP Advisors Inc raised its position in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company’s stock worth $369,000 after purchasing an additional 3,081 shares during the last quarter. Finally, Vident Advisory LLC acquired a new position in shares of Kenvue during the 1st quarter worth approximately $520,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 1.4%

Shares of NYSE KVUE opened at $16.40 on Monday. Kenvue Inc. has a 52-week low of $16.07 and a 52-week high of $25.17. The firm has a fifty day moving average of $20.37 and a 200-day moving average of $21.81. The stock has a market capitalization of $31.48 billion, a PE ratio of 22.17, a P/E/G ratio of 2.36 and a beta of 0.83. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the previous year, the company earned $0.32 EPS. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.1%. Kenvue’s dividend payout ratio is currently 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several research reports. Redburn Partners set a $22.00 price objective on Kenvue in a research report on Friday. Rothschild & Co Redburn upgraded Kenvue from a “neutral” rating to a “buy” rating and cut their price target for the company from $22.50 to $22.00 in a report on Friday. Canaccord Genuity Group cut their price target on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 8th. UBS Group cut their price target on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, July 17th. Finally, Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.12.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.